Lymecycline

Jump to: navigation, search
Lymecycline
Clinical data
Pregnancy
category
Routes of
administration
oral
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability100% (oral)
Metabolism?
Elimination half-life?
Excretionrenal
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaCH23N2O8
Molar mass478.879

WikiDoc Resources for Lymecycline

Articles

Most recent articles on Lymecycline

Most cited articles on Lymecycline

Review articles on Lymecycline

Articles on Lymecycline in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Lymecycline

Images of Lymecycline

Photos of Lymecycline

Podcasts & MP3s on Lymecycline

Videos on Lymecycline

Evidence Based Medicine

Cochrane Collaboration on Lymecycline

Bandolier on Lymecycline

TRIP on Lymecycline

Clinical Trials

Ongoing Trials on Lymecycline at Clinical Trials.gov

Trial results on Lymecycline

Clinical Trials on Lymecycline at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Lymecycline

NICE Guidance on Lymecycline

NHS PRODIGY Guidance

FDA on Lymecycline

CDC on Lymecycline

Books

Books on Lymecycline

News

Lymecycline in the news

Be alerted to news on Lymecycline

News trends on Lymecycline

Commentary

Blogs on Lymecycline

Definitions

Definitions of Lymecycline

Patient Resources / Community

Patient resources on Lymecycline

Discussion groups on Lymecycline

Patient Handouts on Lymecycline

Directions to Hospitals Treating Lymecycline

Risk calculators and risk factors for Lymecycline

Healthcare Provider Resources

Symptoms of Lymecycline

Causes & Risk Factors for Lymecycline

Diagnostic studies for Lymecycline

Treatment of Lymecycline

Continuing Medical Education (CME)

CME Programs on Lymecycline

International

Lymecycline en Espanol

Lymecycline en Francais

Business

Lymecycline in the Marketplace

Patents on Lymecycline

Experimental / Informatics

List of terms related to Lymecycline


Lymecycline is a tetracycline broad-spectrum antibiotic marketed by the pharmeceutical company Galderma[1]. It is approximately 5000 times more soluble than tetracycline base and is unique amongst tetracyclines in that it is absorbed by the "active transport" process across the intestinal wall, making use of the same fast and efficient mechanism by which carbohydrates are absorbed.[2]

The greater absorption of Lymecycline allows for lower dosages to be used; the standard dose of 408 mg is equivalent to 300 mg tetracycline base, and in its action to 500 mg tetracycline hydrochloride. Lymecycline, unlike tetracycline hydrochloride, is soluble at all physiological pH values.

History

Lymecycline was released onto the pharmaceutical market in 1963.

Indications

Lymecycline, like other Tetracyclines, is used to treat a range of infections (see Tetracycline antibiotics group). Its better absorption profile makes it preferable to tetracycline for moderately severe acne and typically prescribed for 8 weeks at a time, but alternatives should be sought if no improvement occurs by 3 months.[3]

Dosage

The standard dose is 408mg (one capsule) twelve hourly by mouth. In particularly severe infections this dose may be increased to 1.224-1.632mg (three or four capsules) daily.

The 408mg once daily dosage for acne aids good drug compliance.

Lymecycline capsules

Formulation

Capsules containing 408mg of Lymecycline (brand name Tetrlysal 300).

References

  1. ^ New Zealand Datasheet August 2003
  2. ^ British National Formulary 45 March 2003

See also

Timeline of antibiotics

hu:Limeciklin th:ไลมีซัยคลิน



Linked-in.jpg